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Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide, 
caused by the degeneration of the dopaminergic neurons in the substantia nigra. Mutations in 
PARK7 (DJ-1) result in early onset autosomal recessive PD, and oxidative modification of DJ-1 
has been reported to regulate the protective activity of DJ-1 in vitro. Glutathionylation is a 
prevalent redox modification of proteins resulting from the disulfide adduction of the glutathione 
moiety to a reactive cysteine-SH; and glutathionylation of specific proteins has been implicated in 
regulation of cell viability. Glutaredoxin 1 (Grx1) is the principal deglutathionylating enzyme 
within cells, and it has been reported to mediate protection of dopaminergic neurons in C. elegans, 
however many of the functional downstream targets of Grx1 in vivo remain unknown. Previously, 
DJ-1 protein content was shown to decrease concomitantly with diminution of Grx1 protein 
content in cell culture of model neurons (SH-SY5Y and Neuro-2A lines). In the current study we 
aimed to investigate the regulation of DJ-1 by Grx1 in vivo and characterize its glutathionylation 
in vitro. Here, with Grx−/− mice we provide evidence that Grx1 regulates protein levels of DJ-1 in 
vivo. Furthermore, with model neuronal cells (SH-SY5Y) we observed decreased DJ-1 protein 
content in response to treatment with known glutathionylating agents; and with isolated DJ-1 we 
identified two distinct sites of glutathionylation. Finally, we found that overexpression of DJ-1 in 
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the dopaminergic neurons partly compensates for the loss of the Grx1 homolog in a C. elegans in 
vivo model of PD. Therefore; our results reveal a novel redox modification of DJ-1 and suggest a 
novel regulatory mechanism for DJ-1 content in vivo.
Graphical Abstract
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Introduction
Parkinson’s disease (PD) is a debilitating neurodegenerative disease caused by the loss of 
dopaminergic neurons in the substantia nigra region of the midbrain [1, 2]. Although the 
etiology of PD is unclear, PD can be categorized into two groups: familial and sporadic. 
These classifications are based on whether PD is attributed to a genetic mutation or if the 
cause of the disease is undefined. In both cases oxidative stress and dysregulation of redox 
homeostasis have been implicated.
LRRK2 (Leucine-Rich Repeat Kinase 2) and DJ-1 (PARK7) are two proteins in which 
genetic mutations are linked to development of PD [3, 4]. Mutations in LRRK2 are shown to 
cause autosomal dominant PD in humans, and over-expression of mutant LRRK2 results in 
dysfunction of dopamine signaling or degeneration of dopaminergic neurons in animal 
models of PD [5, 6, 7, 8, 9]. Mutations in DJ-1 result in autosomal recessive, early onset PD 
in humans, through destabilization and loss of DJ-1 protein content [10]. In addition to 
mutations driving familial PD, post mortem brain samples from patients with sporadic PD 
have been reported to have decreased levels of DJ-1 protein within several areas of the brain 
including the nigral region [ 11]. Although studies have implicated DJ-1 as an anti-oxidant 
factor [12, 13], the molecular mechanism(s) by which DJ-1 protects cells from oxidative 
stress-induced death is currently unresolved [14]. Genetic manipulation has revealed a key 
residue on DJ-1, which is critical for the protection against oxidative stressors. Substitution 
of cysteine 106 with alanine (C106A) results in a “non-functional” DJ-1; over-expression of 
WT, but not C106A DJ-1, protects Park7−/− mouse embryonic fibroblasts from H2O2-
induced cell death [15]. In addition, it has been found that cysteine 106 can be oxidatively 
modified to the sulfinic acid. This modification has been reported to play a critical role in 
protecting M17 neuroblastoma cells from MPP+ toxicity [ 16]. These data suggest that 
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sufficient levels of DJ-1 protein and specific redox modification of DJ-1 play important roles 
in mediating neuronal protection.
Protein S-glutathionylation (Protein-SSG) is a prevalent oxidative modification involving the 
formation of a disulfide bond between glutathione (GSH) and a reactive protein-cysteine-SH 
[ 2]. Protein glutathionylation can result in changes in subcellular localization, protein 
function and/or protein levels [17, 18, 19]. Glutaredoxin 1 (Grx1) is the principal 
deglutathionylating enzyme in the cell, restoring the protein-SH and its function [2]. Grx1 
has been shown to mediate neuronal protection both in vitro and in vivo [19, 20, 21, 22]. We 
recently reported evidence that PD patients have diminished levels of Grx1 specifically 
within the remaining dopaminergic neurons of the midbrain compared to controls [20]. 
Further we found that Caenorhabditis elegans (C. elegans) lacking the homolog of Grx1 
displayed exacerbated losses of dopamine-dependent behavior and dopaminergic neurons in 
models of both familial and sporadic PD [20]. Thus, it appears that Grx1 mediates protection 
of dopaminergic neurons in vitro and in vivo, however the downstream molecular 
mechanism(s) that accomplish this protection remain to be elucidated. In this regard, 
knockdown of Grx1 in model dopaminergic neurons was previously reported to increase cell 
death [21, 22], and to decrease DJ-1 protein content [22]. Over-expression of WT, but not 
C53S or C106S DJ-1, abolished the cell toxicity associated with diminished Grx1 function, 
suggesting that the content of DJ-1, its cysteine redox status, and its effect on neuronal cell 
viability are regulated via Grx1 [22]. Since this interpretation may also apply to our 
observations that loss of the Grx1 homolog in C. elegans exacerbates PD-like phenotypes 
[ 20], we set out in the current study to determine whether Grx1 regulates DJ -1 in vivo.
Here, we report evidence supporting a post-translational mechanism for regulation of DJ-1 
protein content involving reversible glutathionylation and regulation by Grx1 in vivo. 
Accordingly, over-expression of DJ-1 partially compensates for neuronal toxicity due to the 
loss of Grx1 in models of PD.
Methods
Western blot analysis of mouse brain tissue
Mouse brain tissues from two independent cohorts obtained from Case Western Reserve 
University and The University of Vermont (a kind gift from Dr. Y. Janssen-Heininger), were 
dissected into three sections, midbrain, cortex and cerebellum. Midbrain portions of the 
brains were snap frozen in liquid nitrogen. Prior to use, midbrains were homogenized by 
physical disruption using a pestle in a 1.5 ml Eppendorf tube with Cell Lysis Buffer (Cell 
Signaling) containing protease inhibitors (Roche). Tubes were incubated on ice for 15 min 
followed by sonication three times for 5 sec each. Samples were clarified by centrifugation 
at 4°C for 30 min at 16,000 x g. Aliquots of the supernatant (70 μg of protein content) were 
run on a 15% SDS-PAGE gel, transferred to PVDF membrane using a semi-dry transfer 
apparatus (Bio-Rad) at 20 V for 1 h, blocked with 5% milk in Tris-buffered saline with 
0.05% Tween-20 (TBST) for 1 h, and probed overnight with anti-actin (Sigma, diluted 
1:5000), DJ-1 (Abcam,1:5000) and Grx1 (Genscript, 1:1000) antibodies. Blots were washed 
three times for 10 min each in TBST and probed with secondary antibodies (Bio-Rad, 
1:5000) for 1 h. Blots were developed using enhanced chemiluminescence (Thermo Fisher). 
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Rabbit polyclonal anti-Grx1 was generated by Genscript against recombinant human Grx1 
produced in E. coli [ 20]. The western blots were scanned and band densities were quantified 
using ImageJ software (NIH).
Western blot analysis of human brain tissue
Postmortem brain tissue samples from histopathologically diagnosed PD and non-PD cases 
(Supplemental Table A), were used for this study according to approved IRB protocols. 
Frozen tissues of brainstem or pons were obtained from the NICHD Brain and Tissue Bank 
for Developmental Disorders at the University of Maryland (Baltimore, MD), and from the 
Case Western Reserve University/University Hospitals of Cleveland Brain Bank (Cleveland, 
OH). Areas of the frozen brainstem samples containing the substantia nigra were carefully 
dissected and were homogenized with Cell Lysis Buffer (Cell Signaling) plus 1 mM 
phenylmethanesulfonyl fluoride (Sigma) and Protease Inhibitor Cocktail (Sigma). Equal 
amounts of total protein extract were run on a 15% SDS–PAGE gel and transferred to PVDF 
(Millipore). Membranes were blocked in 5% milk in TBST for 1 h. Primary antibodies were 
incubated overnight in 5% milk in TBST, and washed three times in TBST prior to addition 
of the secondary antibody. Secondary antibodies were incubated for 1 h in 5% milk in 
TBST, washed three times in TBST and developed using ECL (Pierce). Antibodies used 
included anti-actin (Sigma), anti-DJ-1 (Abcam) and anti-Grx1 [20].
Western blot analysis of human blood cells
Human blood samples used for this study were collected according to approved IRB 
protocols (see patient information Supplemental Table B). PBMCs from 1.5 ml of 
cryogenically frozen blood were isolated by lysis of the red blood cells in 10 ml red blood 
cell lysis buffer (0.155 M ammonium chloride, 0.01 M potassium bicarbonate, and 0.00013 
M EDTA) for 15 min on a rocker. The suspension was spun at 1,500g on a table-top 
centrifuge, the supernatant was removed, and 10 ml of red cell lysis buffer was added. This 
process was repeated two more times with incubation on the rocker shortened to 5 min each. 
The resulting PBMCs were lysed and were analyzed via western blotting in the same 
manner as described for the western blot analysis of mouse brain tissue except 35 μg of 
lysate was loaded per sample.
Immmunoprecipitation of DJ-1 from mouse brain lysate
Whole snap frozen C57BL/6 or FEB mouse brains were placed in 4 ml cell lysis buffer (Cell 
Signaling) plus 50 mM iodoacetamide (to block free cysteine-SH). Brains were 
mechanically homogenized via mortar and pestle, and then subjected to lysis via sonication 
on ice for 2 min, alternating 10 s on 10 s off. Lysate was then spun down at 16,000g at 4°C 
in a tabletop centrifuge for 1 hour. The resulting supernatant was divided into aliquots, with 
addition of either 50 μl Protein G beads (Pierce) and 5 μg anti-goat IgG (Santa Cruz); or 50 
μl Protein G beads and 5 μg anti-DJ-1 (Goat, Abcam). Samples were rotated at 4°C for 48 h, 
washed three times in lysis buffer plus 0.25 M NaCl. Laemmeli sample buffer (without 
reducing agents) was added and beads were boiled for 10 min. Samples were then run on a 
15% non-reducing SDS-PAGE gel, transferred to a PVDF membrane, and probed for 
glutathionylation using an anti-glutathione antibody (anti-GSH, Millipore). Membranes 
were stripped by incubation in 0.1 M Tris-HCl pH 6.8, 2% SDS, and 0.11 M β-mercapto 
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ethanol at 50°C for 30 min followed by three washes in TBST for 15 min each. Blots were 
then probed with rabbit anti-DJ-1 (Cell Signaling) in the same manner as described above.
LC-MS analysis of proteins and peptides
Mass spectrometric (MS) analyses were performed using a LTQ Velos dual-pressure linear 
ion trap mass spectrometer equipped with an Accela 600 quaternary pump for in-line protein 
and peptide high performance liquid chromatography (HPLC) separation and an 
electrospray ionization source (Thermo Scientific, Waltham, MA). The electrospray 
ionization source was operated in the positive ion mode with the following parameters: 
normalized collision energy 35 kV, capillary temperature 300 °C, source voltage 5 kV, 
capillary voltage 43 V, and tube lens 105 V. Mass spectra were collected over a 200–2000 
m/z range. To record mass spectra of intact proteins, 0.5 μg of DJ-1 or its glutathionylated 
form was loaded onto an XBridge BEH300 C4 column (3.5 μm, 2.1 × 50 mm) (Waters, 
Milford, MA) and eluted with a linear gradient (5–100%) of acetonitrile in water containing 
0.1% formic acid. The gradient was developed over 20 min at a flow rate of 0.25 ml/min.. 
Masses of the proteins were calculated by deconvolution of intact protein ions using 
ProMass for Xcalibur software (Thermo Scientific). The same instrumentation including 
column and solvents was employed to separate peptide products of tryptic digestion of DJ-1. 
However, to ensure adequate peptide separation the gradient of acetonitrile was developed 
over 40 min. The protein tryptic digestion was performed in 50 mM Tris-HCl, pH 7.5, at 
37 °C overnight. Products of the reaction were directly analyzed by LC-MS. Peptides were 
identified based on a correlation of their tandem-mass spectra (MS/MS) with theoretically 
predicted ion fragmentation patterns.
The efficiency of protein glutathionylation was assessed by relative quantification of 
unmodified DJ-1 in the reaction sample. For this purpose, prior to the tryptic digestion, the 
glutathionylated DJ-1 sample was supplemented with an equal amount (12.5 μg) of 15N-
labeled DJ-1. LC-MS analysis of the tryptic peptide mixtures revealed co-eluting native 
and 15N-labeled peptides. The relative ion intensities for pairs of native and 15N-labeled 
peptides at the same charge state were used to calculate the relative abundance of 
unmodified DJ-1 and thus the fraction of glutathionylated protein. Glutathionylation of 
cysteine residues were estimated using unmodified 15N DJ-1 as an internal standard. 
Quantification of modified tryptic peptides were estimated by subtraction of the peak areas 
of the non-modified peptides in the treated 14N-samples from those in the untreated 15N-
samples.
C. elegans strains and maintenance
A list of C. elegans strains with their designation, corresponding genotype, and strain 
nomenclature is shown in Supplemental Table C. C. elegans strains were maintained on 
nematode growth medium (NGM) plates with E. coli OP50 as a bacterial food, as previously 
described [6].
Single-worm PCR
Individual worms were placed in PCR tubes containing 10 μl total volume consisting of 1x 
OneTaq buffer (New England Biolabs) and 0.5 mg/ml proteinase K (Sigma). Worms were 
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frozen on dry ice for 15 min, then lysed via incubation at 65°C for 90 min followed by 95°C 
for 30 min. PCR amplifications were performed using OneTaq polymerase following 
manufacturer’s instructions (New England Biolabs). Identification of WT and mutant djr-1.2 
DNA was accomplished using the following primers (Integrated DNA Technologies), 
Forward: 5′-GCAAACTCGAAAGCAGTTGC-3′, Reverse WT: 5′-
CGTATTGTTCCGGACGTAGC-3′ Reverse knockout: 5′-
TTTGACCGTGTTCTTTGTCG-3′. Identification of LRRK2 and glrx-10 DNA was 
accomplished using the primers described previously [20].
Generation of C. elegans expressing Pdat-1::mCherry or Pdat-1::DJR1.2::mCherry in 
dopaminergic neurons
Plasmids containing Pdat-1::mCherry and Pdat-1::DJR-1.2::mCherry were constructed in the 
backbone of the pFxneRFP vector (a generous gift of Dr. S. Mitani, Tokyo Women’s 
Hospital, Japan). The Pdat-1 insert was excised from the Pdat-1::pFxneEGFP plasmid [6] 
using the KpnI and HindIII sites. The DJR-1.2 open reading frame was PCR amplified from 
the DJR-1.2_pDONR201 plasmid (GE) with primers containing the BamHI and Xho1 sites, 
Forward 5′-GATATAGGATCCATGGCTGCCCAAAAGAG-3′ and Reverse 5′-
GTACTACTCGAGTACTTTGCCAAACACAG-3′. The mCherry insert was obtained by 
PCR amplification from the pGH8 plasmid (Addgene) with primers containing the NotI and 
BglII sites, Forward 5′-ATAATAGCGGCCGCTTAATGGTCTCAAAG-3′ and Reverse 5′-
GCGCGCGAGATCTACTACTTATACAATTCATCC-3′. Restriction digestion was 
performed with appropriate selective enzymes according to the manufacturer’s instructions 
(New England Biolabs). PCR products were purified with the QIAquick PCR purification kit 
(Qiagen). All DNA fragments were run on 1% agarose gels, followed by extraction with the 
QIAquick gel extraction kit (Qiagen). DNA inserts were ligated into pFxneRFP vector at 
room temperature for 2.5 h using T4 ligase (New England Biolabs) to generate the Pdat-1:: 
mCherry and Pdat-1::DJR-1.2::mCherry plasmids. The plasmids were transformed into E. 
coli DH5α cells (Life Technologies), propagated, purified on Qiagen miniprep columns, and 
verified by DNA sequencing. The DNA constructs were microinjected into C. elegans N2 
strain by Knudra Transgenic (Murray, Utah). Stable worm lines with red fluorescent 
dopaminergic neurons expressing mCherry (Pdat-1::mCherry) or DJR-1.2 fused with 
mCherry (Pdat-1::DJR-1.2::mCherry) were selected, and their genotypes were verified by 
PCR.
Basal slowing assay
The basal slowing assay was performed as previously described [6]. Briefly, NGM assay 
plates were seeded with a ring of E. coli OP50. Age-synchronized worms were transferred to 
a non-seeded NGM plate and washed twice in S basal buffer (100 mM NaCl, 10 μg/ml 
cholesterol, 50 mM potassium phosphate, pH 6.0). Worms were then transferred to either 
seeded or non-seeded assay plates, allowed to recover for 5 min, and their body bends were 
recorded in 20 s intervals.
Dopaminergic neuron counting
Approximately 30 age-synchronized adult worms were placed into 200 μl of 10 mM 
tetramisole (Sigma) in raised wall four chamber slides (Lab-Tek). GFP neurons were 
Johnson et al. Page 6
Biochemistry. Author manuscript; available in PMC 2016 August 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
visualized with a Nikon microscope at 20x zoom. Dopaminergic CEP and ADE head 
neurons were assessed for degeneration in a blinded fashion, according to published 
protocols [ 20]. Neurons with detectable GFP signal were counted as positive, neurons 
lacking cell body GFP signal were counted as negative.
Treatment and analysis of SH-SY5Y cells
SH-SY5Y cells (ATCC) were grown in OPTI -MEM (Invitrogen) + 10% fetal bovine serum 
(Atlanta Biological) at 37 °C with 5% CO2. For H2O2 treatment, cells were treated with 
increasing concentrations of H2O2 for 2 h as indicated in the figure legend. For diamide 
treatment experiments, cells were pretreated with either 10 μM MG-132 (Sigma) diluted in 
DMSO, 1 μM lactacystin (Santa Cruz) diluted in DMSO, 1:200 dilution of cell culture broad 
protease inhibitors (Sigma) diluted in DMSO, or DMSO (0.5%) for 7 h. Cells were then 
treated with 0.1 mM diamide or PBS for 2 h. All cells were lysed in Cell Lysis Buffer (Cell 
Signaling) containing protease inhibitors (Roche) on ice for 15 min with occasional mixing 
(Vortex). Lysates were spun down at 4°C for 30 min at 16,000 x g in a table-top centrifuge. 
The supernatant (35 μg of protein) was loaded onto a 15% SDS-PAGE gel and western 
blotting was completed in the same manner as the mouse midbrain tissue described above.
Validation of glutathionyl mixed disulfide specificity of the anti-GSH Antibody
Glutathionylation of proteins can be reversed by addition of disulfide reducing agents. In 
order to validate the interpretation of the reactivity of the anti-GSH antibody, anti-DJ-1 
beads were used to immunoprecipitate DJ-1 from mouse brains, and the resultant effluent 
was processed on a non-reducing SDS-PAGE gel and transferred to a PVDF membrane. 
After transfer the blot was blocked in 5% milk for 1h and cut in half. Half of the blot was 
incubated with buffer and the other half was incubated with buffer plus 100 mM 
dithiothreitol (DTT) for 30 min. The blots were then washed and probed with the anti-GSH 
antibody overnight. The blot incubated in buffer alone revealed the prominent band at 45 
kDa while the blot incubated in buffer plus DTT failed to show immunoreactivity at 45 kDa 
(Supplemental Figure S4). Blots were then stripped and re-probed for DJ-1 confirming the 
presence of DJ-1 on both halves of the membrane.
Generation of recombinant DJ-1
Recombinant DJ-1 was purified following the protocol described in [23]. Briefly 1.5 L of 
BL21(DE3) E. coli containing pET15b-DJ-1 was induced with 1 mM IPTG for 4 h. Cells 
were spun down and lysed via lysozyme treatment followed by sonication. Centrifugally 
cleared lysate containing 6x-His tagged DJ-1 was bound to Ni2+ His-select resin (Sigma), 
washed, eluted with 200 mM imidazole, cleaved with thrombin, and dialyzed overnight. 
Uncleaved DJ-1 was removed using a second pass over the Ni2+ column, thrombin was 
removed using benzamidine-sepharose resin, and co-purifying nucleic acids were removed 
from DJ-1 using a Q-sepharose column. DJ-1 (free of the 6x-His tag) was then concentrated 
and snap frozen in liquid nitrogen.
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Generation of 15N labeled DJ-1
Recombinant uniformly 15N-labeled DJ-1 was generated as previously described [23]. 
Briefly, N-terminally 6x-His tagged DJ-1 was expressed from pET15b in BL21(DE3) E coli. 
An inoculum of the cells was grown overnight in LB media containing 100 μg/ml ampicillin 
at 37°C. 50 ml of this culture was spun down and washed twice in 10 ml of sterile 15NH4Cl 
M9 defined media [23] and transferred to 1 L of 15NH4Cl M9 media. These cells were 
grown at 37°C and DJ-1 expression was induced by the addition of 0.5 mM IPTG when the 
A600 = 0.5. Protein purification was performed as described above. 15N labeling efficiency 
was determined using mass spectrometry as described [23] and the incorporation efficiency 
was >99%.
RNA isolation and qPCR Methods
Midbrain tissue from C57BL/6 and BALBc Grx1−/− mice and age- and sex-matched controls 
(when available) was homogenized in 1mL TRIzol (Life Technologies) using a Teflon and 
glass mortar and pestle. RNA was isolated according to manufacturer’s instructions. 
Resulting RNA was converted to cDNA using SuperScriptII (Invitrogen) according to 
manufacturer’s instructions. Park7 (DJ-1) expression (probe Mm00498538_m1) was 
analyzed using TaqMan Fast Universal PCR mix (Life Technologies) on the StepOnePlus 
machine (Life Technologies) using StepOne v2 software. Park7 expression was normalized 
to Gapdh (probe Mm99999915_g1) expression as an internal control.
RESULTS
Grx1 controls DJ-1 protein expression in vivo.
As reported previously, knockdown of Grx1 via shRNA results in decreased DJ-1 protein 
content in the SH-SY5Y [21] and Neuro2A cell lines[ 22], however it is unknown if Grx1 
plays a role in mediating DJ-1 protein content in vivo. Midbrain lysates from Grx1−/− and 
WT mice in the C57BL/6 background from two independent cohorts were subjected to 
western blot analysis, in order to investigate the potential control of DJ-1 by Grx1. Western 
blot analysis indicated that Grx1−/− mice have diminished levels of DJ-1 protein compared 
to WT controls (Figure 1 A, B). Quantitative PCR was used to measure the mRNA levels of 
DJ-1 in the Grx1−/− and WT mice in the C57BL/6 background. No statistical difference was 
found in the mRNA levels between the Grx1−/− and WT mice (Supplemental Figure S1A). 
We also analyzed DJ-1 content in brain samples (kindly provided by Reiko Matsui, Boston 
University) from transgenic mice in which hGRx1 was overexpressed so that total Grx1 
content (human plus mouse) was about 2-fold higher relative to WT mice [ 24]. In this case 
the DJ-1 content was not different (transgenic vs. WT), suggesting that the normal content of 
Grx1 is sufficient to maintain DJ-1 content, at least in the absence of increased oxidative 
stress (Supplemental Figure S1B). Notably, we also analyzed midbrain lysates from Grx1−/− 
and WT mice in the BALB/c background and these mice did not show a difference in the 
DJ-1 protein or mRNA content (Supplemental Figure S1 C, D); thus indicating that 
differential genetic expression and/or posttranslational regulation in the BALB/c strain 
disconnects the regulatory effect of Grx1 on DJ-1.
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In addition, to investigate whether DJ-1 and Grx1 protein levels correlate in human tissue, 
lysates from human peripheral blood mononuclear cells (PBMCs) and post-mortem 
midbrain tissue were subjected to western blot analysis. Protein levels of Grx1 and DJ-1 
(normalized to actin) showed a significant positive correlation for protein isolated from both 
PBMCs (Figures 1 C) and midbrain tissue (Figures 1 D; blots are shown in Supplemental 
Figure 2S A, B). Taken together, these data provide in vivo evidence for the first time that 
Grx1 influences DJ-1 protein content in the midbrains of mice, and that Grx1 and DJ-1 
protein contents are co-variant inhuman tissue s.
Treatment of cells with glutathionylation-inducing agents results in loss of DJ-1 protein
As noted, knockdown of Grx1 in model dopaminergic neuronal (Neuro2A) cells via shRNA 
resulted in decreased DJ-1 protein, but not mRNA content [22]; however the mechanism by 
which this loss of DJ-1 protein occurred remains unclear. We hypothesized that loss of Grx1 
results in accumulation of glutathionylated DJ-1 (DJ-1-SSG), which is then rapidly 
degraded. In order to test whether agents that promote DJ-1-SSG formation result in loss of 
DJ-1 content, SH-SY5Y cells were treated acutely with H2O2, which is known to result in 
protein-SSG formation [25, 26]. DJ-1 protein content was selectively diminished in a dose 
dependent manner (relative to actin, which is known to be glutathionylated without affecting 
its content) (Figure 2 A, B). Since H2O2 can modify cysteine residues to sulfinic and 
sulfonic acids in addition to protein-SSG, we wanted to limit the modification to 
glutathionylation of DJ-1. Accordingly, cells were treated separately with diamide, an 
oxidizing agent characterized to promote selective formation of protein-SSG [27, 28, 29]. 
Western blot analysis indicated that treatment with diamide also resulted in a significant loss 
of DJ-1 protein content compared to untreated controls. (Figure 2 C, D). Notably, the extent 
of diminution in DJ-1 protein content (~40%) was similar for both the H2O2- and diamide-
treated cells. It was previously reported that loss of DJ-1 content concomitant with 
knockdown of Grx1 could be limited by treatment with a cocktail of inhibitors of 
proteolysis, consistent with the concept of enhanced degradation [22]. In order to learn 
whether loss of DJ-1 after diamide treatment of SH-SY5Y cells displayed the analogous 
pattern of non-proteasomal proteolysis as observed in Grx1-dificient Neuro2A cells [22], we 
pretreated the SH-SY5Y cells with the proteasome inhibitor MG-132 or with a broad 
protease inhibitor (PI) cocktail prior to diamide treatment [22]. Pretreatment with the broad 
protease inhibitors, prevented the diamide induced loss of DJ-1 (Figure 2 C, D). Notably, 
pretreatment of SH-SY5Y cells with either MG-132 or lactacystin inhibited the proteasome 
(as indicated by increased β-catenin content (Figure 2, E, G), but failed to blunt the diamide-
induced loss of DJ-1 protein (Figure 2 E, F). These data suggest that treatment of SH-SY5Y 
cells with glutathionylation-inducing agents results in DJ-1 degradation in a proteasome-
independent manner.
DJ-1 is glutathionylated in vivo
DJ-1 contains three cysteine residues located at positions 46, 53, and 106. Cysteines 53 and 
106 have been reported previously to be oxidatively modified [23, 30], but there is no 
evidence for glutathionylation of DJ-1 in a physiological setting. In order to determine if 
DJ-1 undergoes glutathionylation in vivo, DJ-1 was immunoprecipitated from whole mouse 
brain homogenates and subjected to non-reducing SDS-PAGE and western blot analysis. 
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Using an antibody that recognizes glutathionylated moieties (anti-GSH), we observed a 
prominent band at approximately 45 kDa (Figure 3 A, arrow). The blot was stripped and re-
probed with an anti-DJ-1 antibody, which resulted in a band at the same molecular weight as 
recognized by the anti-GSH antibody. (Figure 3 B). The band located at approximately 45 
kDa corresponds to the size of the dimeric DJ-1. This suggests that dimeric DJ-1-SSG can 
form an intermolecular bond between two DJ-1 monomers either in the cell or while running 
through the electric field in the gel. In order to validate that the approximately 45 kDa band 
is DJ-1 and not a non-specific band, mouse brain homogenates were immunoprecipitated 
with anti-DJ-1 beads to isolate DJ-1, and the sample was split into two aliquots. One aliquot 
was reduced with 100 mM dithiothreitol (DTT) and the other was left non-reduced; then the 
two samples were analyzed on western blots. The ~45 kDa band appeared in the non-
reduced lane, but in the reduced lane a single band was present at approximately 22 kDa, 
corresponding to the molecular weight of monomeric DJ-1 (Supplemental Figure S3A). In 
addition, western blot analyses with the anti-DJ-1 antibody were performed with DTT-
treated lysates of brain samples from WT and DJ-1−/− mice (a kind gift from Vera Bonilha, 
Cleveland Clinic Foundation). An immunoreactive band appeared at approximately 22 kDa 
as expected for the WT samples; but no band was present for the samples from the DJ-1−/− 
mice, documenting the specificity of the anti-DJ-1 antibody (Supplemental Figure 3S B).
Glutathionylation of proteins can be reversed by disulfide reducing agents. To confirm the 
interpretation of the reactivity of the anti-glutathione antibody, DJ- was immunoprecipitated 
from mouse brains, run on a non-reducing SDS-PAGE gel and transferred to a PVDF 
membrane. After transfer half of the blot was then incubated with 100 mM dithiothreitol 
(DTT) for 30 min to reduce glutathionylated cysteines. The blot incubated with DTT lost 
immunoreactivty with the anti-GSH antibody(Supplemental Figure 4S). Blots were then 
stripped and re-probed for DJ-1 confirming the presence of DJ-1 on both halves of the 
membrane. These data show that treatment with DTT results in ablation of reactivity with 
the anti-glutathione antibody, consistent with the conclusion that DJ-1 is glutathionylated 
within the midbrains of mice. It was also confirmed separately that actin which is known to 
be glutathionylated in intact cells[ 31] and has a similar molecular weight (42 kDa) to 
dimeric DJ-1 was not detected on the blot of the immunoprecipitated DJ-1 (data not shown).
Preferential glutathionylation of DJ-1 at cysteines 53 and 106
To further characterize the glutathionylation of DJ-1, 12.5 μg of pure recombinant DJ-1 was 
incubated with 5 mM GSH and 1 mM diamide for 30 min and subjected to liquid 
chromatography-mass spectrometry (LC-MS) analysis. MS spectra of the untreated (Figure 
3 C) and treated (Figure 3 D) intact protein revealed two distinct sets of ions in the treated 
sample as compared to untreated DJ-1. The deconvoluted spectrum of untreated DJ-1 
revealed the expected protein mass of 20036.3 Da, equal to the theoretical mass of the 
polypeptide based on the amino acid sequence. Reaction with GSH and diamide resulted in 
increases of 305 and 610 Da in the protein mass to 20341.5 and 20646.7 Da, corresponding 
to the additional masses of a single and two glutathionyl moieties covalently attached to 
DJ-1 (Figure 3 D).
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To identify the sites of glutathione adduction, the glutathionylation reaction was repeated; 
the DJ-1 reaction mixture was dialyzed to remove GSH/diamide, digested with trypsin, and 
subjected to tandem MS/MS analysis. The trypsin digests clearly revealed the presence of 
two covalently modified peptides DVVIC53PDASLEDAK (m/z = 766.5 [M+2H]+2) and 
GLIAAIC106AGPTALLAHEIGFGSK (m/z = 756.4 [M+3H]+3) in the GSH/diamide treated 
sample (Figure 4 C–D) as compared to the unmodified DJ-1 (Figure 4 A–B). The identity of 
each of the peptides and sites of modification were confirmed by their MS/MS 
fragmentation patterns. A 305-Da shift in the b- and y-ion series observed between the 
modified and unmodified peptides indicated glutathionylation on the side chains of the 
Cys-53 (Figure 4 E) and Cys-106 (Figure 4 F) residues.
In order to estimate the relative extents of glutathionylation of the different cysteine 
residues, “light DJ-1” (14N, natural abundance) was treated with GSH and diamide. An 
equimolar amount of “heavy DJ-1” (15N-labeled) was untreated and used as an internal 
standard. Both 14N- and 15N-proteins were digested with trypsin, and subjected to LC-MS 
analysis (Supplemental Figure 5S, A–E). Quantification of the peak areas for the non-
modified peptides indicated that major glutathionylation occurs at cysteine residues Cys53 
and Cys106. The extent of glutathionylation was estimated by subtracting the peak area of 
the treated non-modified peptide (14N) from the peak area of the untreated standard peptide 
(15N), giving a value for the peak area of the glutathionylated peptide. Accordingly, the 
extent of glutathionylation of Cys53 and Cys106 were calculated to be 70 and 77%, 
respectively (Table 1). We did find a very minor fraction (~7%) of glutathionylated Cys46 
(Table 1), but this was likely due to heterogeneity within the preparation of DJ-1 and/or 
unfolding of the protein in solution, as Cys46 is known to be buried in the hydrophobic core 
of the protein [ 32]. Taken together, our data show that isolated recombinant DJ-1 is 
preferentially glutathionylated at cysteine resides 53 and 106.
Loss of DJ-1 homolog exacerbates LRRK2-mediated dysfunction of dopamine-dependent 
movement in C. elegans
Overexpression of DJ-1 has been shown to mediate dopaminergic neuronal protection 
against LRRK2 toxicity in vitro [ 33]. In order to investigate the potential neuroprotective 
role of DJ-1 in vivo, we chose to use C. elegans as a model because of the simplicity of the 
dopaminergic neuronal system. C. elegans worms contain two distinct homologs to human 
DJ-1, DJR-1.1 and DJR-1.2. Two independent groups have reported that DJR-1.1 is 
expressed highly in the intestine and not within the head neurons [34, 35]. DJR-1.2, in 
contrast, has been reported to be expressed in the dopaminergic neurons of the worms [35]. 
Therefore, we used DJR-1.2-deficient animals in this study. Genetic crosses were made 
between the djr-1.2−/− strain and transgenic animals expressing GFP in the dopaminergic 
neurons (used as WT control). In addition, the djr-1.2−/− strain was crossed with lines that 
co-express GFP and pathogenic human LRRK2 mutants in the dopaminergic neurons 
(G2019S-LRRK2 or R1441C-LRRK2, hereafter referred to as G2019S and R1441C, 
respectively) [6]. Crosses were confirmed via PCR genotyping of djr-1.2 and LRRK2(Figure 
5A).
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We examined the functional integrity of dopaminergic signaling in the C. elegans lines using 
a well-established assay of dopamine-dependent behavior, termed the basal slowing assay 
[36]. In agreement with our previous findings, transgenic expression of either G2019S or 
R1441C in the dopaminergic neurons of C. elegans resulted in age-dependent loss of 
dopamine-dependent movement behavior [6, 20]. Compared to WT, the mutant djr-1.2−/− 
worms displayed a late onset loss of dopamine-dependent behavior on adult day 2 (Figure 
5B). These data are in agreement with the previous finding that dauer-stage C. elegans 
lacking djr-1.2 have a dopamine signaling defect [35]. Moreover, the hybrid lines, both 
deficient in DJR-1.2 and expressing G2019S or R1441C, displayed a more robust loss of 
dopamine-dependent behavior (Figure 5B). We also examined the morphological integrity of 
the GFP labeled-dopaminergic neurons via microscopy in young and aged worms. 
Expression of G2019S or R1441C resulted in an age dependent loss of dopaminergic 
neurons as previously documented [ 6, 20]. The djr-1.2−/− mutant strain showed decreased 
survival of dopaminergic neurons compared to WT on adult day 8 (Figure 5C). Exacerbation 
of dopaminergic neuronal loss in the lines lacking DJR-1.2 and expressing LRRK2 mutants 
was limited and seen only on adult day 2 in the R1441C; djr-1.2−/− line. These data indicate 
that loss of DJR-1.2 in vivo results in diminution of dopamine-dependent behavior, 
exacerbation of mutant LRRK2-induced diminution of dopamine-dependent behavior, but 
only incomplete dopaminergic degeneration and limited exacerbation of LRRK2 -mediated 
dopaminergic degeneration.
Over-expression of DJ-1 homolog partially compensates for the loss of Grx1 in R1441C-
mediated neurotoxicity
We previously found that loss of GLRX-10, the worm homolog of Grx1, exacerbates 
LRRK2-mediated dopaminergic dysfunction [20]. Our current data analyzing midbrain 
homogenate from Grx1−/− mice indicates that loss of Grx1 results in a decreased protein 
content of DJ-1 in vivo(Figure 1 A, B), indicating that regulation of DJ-1 content is 
functionally downstream of Grx1. Synthesizing these observations, we hypothesized that the 
exacerbation of LRRK2 toxicity by deficiency of the Grx1 homolog in C. elegans [20] is 
due, at least in part, to increased glutathionylation and consequent loss of DJ-1. In order to 
test if DJ-1 overexpression could rescue the Grx1 deficiency, we generated R1441C; 
glrx-10−/− worms specifically expressing DJR-1.2 fused to red fluorescent protein mCherry 
(DJR-1.2-mCherry) or mCherry (vector control) in the dopaminergic neurons. The 
compound worm lines were confirmed via PCR (Figure 6A) and fluorescence microscopy 
(Figure 6B). These worms were subjected to the basal slowing assay to assess their 
dopamine-dependent behavior.
Consistent with the previous report [20], R1441C; glrx-10−/− worms displayed a robust loss 
in dopamine-dependent behavior. Expression of the mCherry control in the R1441C; 
glrx-10−/− line resulted in no change in basal slowing response compared to its cognate 
strain (Figure 6C). Overexpression of DJR-1.2-mCherry in the dopaminergic neurons of the 
R1441C; glrx-10−/− worms showed significant improvement in basal slowing response 
compared to the R1441C; glrx-10−/− worms expressing the vector control on adult Day 0, 
and continued to show apparent but not statistically significant improvement on adult days 1 
and 2. These data indicate that expression of DJR-1.2 can partially rescue the pathogenic 
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LRRK2 induced dysfunction of dopamine-dependent behavior in C. elegans lacking 
GLRX-10.
Discussion
DJ-1 plays an important role in mediating dopaminergic neuronal protection. De -stabilizing 
mutations in DJ-1 result in familial PD, and diminished protein content of DJ-1 has been 
reported in sporadic cases of PD [ 10, 11]. Furthermore, knockout or knockdown of DJ-1 
results in increased susceptibility to toxin-induced dopaminergic cell death in vivo [37, 38]. 
These studies indicate that protein levels of DJ-1 play an important role in protecting against 
dopaminergic degeneration. Hence, deciphering the mechanisms of regulation of DJ-1 
protein content represents an important focus of study in PD biology.
Reversible glutathionylation of proteins is recognized as an important regulatory mechanism 
for pathways that mediate cell death/viability [ 39]. For example, the FAS receptor is a 
signal transducing receptor that upon activation via Fas-ligand drives cell death through 
activation of the death domain. Fas-induced cell death has been shown to be regulated in part 
by glutathionylation at cysteine 294 [17]. Treatment of lung fibroblasts with Fas-ligand 
resulted in cell death when WT-Fas, but not C294A-Fas was expressed [ 17], suggesting that 
glutathionylation of Fas is a pre-requisite for cell death signal transduction. In addition, 
glutathionylation of the cell survival kinase Akt has been associated with decreased Akt 
activation and reduced cell viability in the human fetal retinal pigment epithelial cells when 
challenged with H2O2 [ 40]. Conversely, overexpression of Grx1 resulted in decreased levels 
of Akt glutathionylation in response to H2O2 and increased activation of Akt signaling [ 40]. 
These and other studies demonstrate the functional impact of selective protein 
glutathionylation on cell viability under stress conditions.
Our previous data revealed that Grx1 protein content was decreased in post-mortem samples 
of brain tissue from[ 20]. Our current data supports the interpretation that Grx1 regulates 
DJ-1 protein content in vivo and that DJ-1 is susceptible to glutathionylation in vitro and in 
vivo. Additional data supporting the idea that DJ-1 is regulated by glutathionylation have 
been reported. Unlike WT DJ-1, the C106A and C53A mutants of DJ-1 are resistant to 
degradation in Neuro2A cells in which Grx1 was knocked down [22]. Our current finding 
that cysteine residues 53 and 106 are more readily glutathionylated than cysteine 46 is 
consistent with data from the crystal structure of DJ-1 indicating that cysteine 46 is not 
solvent accessible and buried within the protein [32]. We hypothesize that glutathionylation 
of DJ-1 regulates its protein level in the cell. Consistent with this interpretation, treatment of 
SH-SY5Y cells with two known inducers of glutathionylation resulted in decreased DJ-1 
protein content. This decrease in DJ-1 protein can be abrogated by pre-treatment with non-
specific protease inhibitors suggesting that the loss of DJ-1 is caused by proteolytic 
degradation following glutathionylation. The result is in agreement with previously 
published data indicating that loss of Grx1 via shRNA knockdown in Neuro2A cells results 
in a loss of DJ-1 protein content [22]. In order to identify which component(s) of the 
proteolytic inhibitor cocktail blocked DJ-1 degradation and therefore which pathway(s) is 
dysregulated, we treated Neuro2A cells with the individual components and then knocked 
down Grx1 via shRNA. As expected, knockdown of Grx1 resulted in a loss of DJ-1 protein 
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content; however none of the individual components alone blunted the Grx1 knockdown-
mediated loss of DJ-1 (Supplemental Figure 7S, A–F). These data suggest a complex 
mechanism of degradation likely involving multiple enzymes contributing to regulation of 
DJ-1 degradation.
In order to test whether DJ-1 plays a functional role in regulating dopaminergic viability in 
concert with Grx1in vivo we used C. elegans as a model system. We previously found that 
C. elegans lacking GLRX -10, the Grx1 homolog, displayed an exacerbation of the 
neurodegenerative phenotype in both familial and sporadic models of PD [ 20]. Our 
observation of decreased levels of DJ-1 in Grx1−/− mice led us to hypothesize that decreased 
DJ-1 could be at least partly responsible for the more toxic PD-like phenotype in the C. 
elegans lines lacking GLRX-10. Protein content of DJ-1 within the glrx-10−/− worms was 
not determined because the antibodies for human DJ-1 failed to specifically recognize C. 
elegans DJR-1.2 (data not shown). As an alternative approach to test if an elevated content 
of DJ-1 could compensate for the loss of GLRX-10 in C. elegans, DJR-1.2 was specifically 
expressed in the dopaminergic neurons of R1441C-LRRK2; glrx10−/− worms. Using the 
well-established basal slowing assay to determine integrity of dopamine-dependent behavior, 
we found that expression of DJR-1.2 could partially compensate for the loss of GLRX-10. 
Indeed, the protective effect of DJ-1 appears to occur early in the life of the worm and then 
fades in adulthood (Figure 6C). Fluorescence microscopic analysis was conducted on adult 
days 0 and 2 to assess levels of mCherry in control worms or in worms expressing 
exogenous mCherry-tagged DJ-1 protein. Quantification of mCherry/GFP intensity showed 
no difference in the expression of exogenous mCherry in the control lines on adult days 0 
and 2 as expected (Supplemental Figure S6, left panel). Notably there was also no change in 
the mCherry/GFP ratio in the DJ-1:mCherry worms (Supplemental Figure S6, right), 
indicating that diminution of DJ-1 mediated protection with age is not due to a loss of the 
exogenous DJ-1 protein. These data suggest several alternative hypotheses for why the effect 
of the overexpressed DJ-1 fades with time, including (a) the levels of exogenous DJ-1 fail to 
sustain protection due to an increased burden of ROS over time in these LRRK2-expressing 
worms: (b) DJ-1 is functionally inactivated in the worms due to increased ROS; and (c) the 
DJ-1 mediated dopaminergic neuronal protection involves co-factors that may be deactivated 
by glutathionylation in the absence of the Grx1 homolog. One or more of these hypotheses 
may be supported by previous findings. For example, it has been reported that pathogenic 
LRRK2 drives increased ROS expression in vitro [ 41]; DJ-1 has been reported to exist in a 
(possibly inactive) sulfonic acid state after oxidative challenge [42]; the glutathionylated 
protein database [ 43] reports that the DJ-1 binding partner thioredoxin-1 can be 
glutathionylated. Taken together these observations provide a plausible explanation for the 
transient protective effect of elevation of DJR-1.2 content, contributing some compensation 
for loss of the Grx1 homolog and some protection against mutant LRRK2-mediated toxicity 
in vivo.
Although DJ-1 provides some protection against exacerbation of LRRK2 toxicity by 
glutaredoxin deficiency, the lack of complete rescue indicates that other protein(s) also likely 
play a role in mediating Grx1 neuronal protection. For example, Akt1 is a well-established 
survival kinase that has been shown to play neuroprotective roles in a variety of contexts 
including PD [ 44]. Notably, the G2019S- and R1441C-LRRK2 mutants showed a decreased 
Johnson et al. Page 14
Biochemistry. Author manuscript; available in PMC 2016 August 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
ability to phosphorylate and activate Akt1 in vitro, suggesting that pathogenic mutations of 
LRRK2 drive toxicity at least in part through loss of a critical cell survival signaling 
mechanisms involving Akt [ 45]. Proper activation/regulation of Akt is critical for Akt 
mediated protection. Considering the context of Grx1 deficiency, it is important to note that 
Akt1 has been reported in other contexts to be regulated both directly [40] and likely 
indirectly [46] through reversible protein glutathionylation. Thus, treatment of human retinal 
pigment epithelial cells with H2O2 resulted in Akt1 glutathionylation, impaired 
phosphorylation of Akt1, and cell death [40]. Over-expression of Grx1 resulted in decreased 
levels of glutathionylated Akt1, normalized phosphorylation/activation of Akt1, and 
increased cell viability when challenged with H2O2 [40]. These data indicate that 
glutathionylation of Akt itself or of regulators of Akt may interfere with its cell-survival 
activity. In particular, Akt1 is positively regulated through phosphorylation by the upstream 
kinase PKC [47], and PKC itself appears to be negatively regulated by glutathionylation 
[43]. Thus, purified recombinant PKC treated with diamide and 35S-GSH was found to be 
glutathionylated and inactivated. Furthermore, glutathionylation of intracellular PKC was 
confirmed by documenting DTT-reversible incorporation of 35S-radioactivity into PKC that 
was immunoprecipitated from diamide-treated NIH3T3 cells in which GSH had been 
radiolabeled [46]. These data suggest that glutathionylation and concomitant inactivation of 
PKC would decrease Akt1 phosphorylation and result in an impaired ability to respond to 
stress. Taken all together, loss of Grx1within dopaminergic neurons besides affecting cell 
viability through diminution of DJ-1 may also result in an impaired stress response due to 
hyper-glutathionylation of PKC and Akt. The increased glutathionylation and consequent 
inactivation of DJ-1 and the Akt pathway may combine to explain the exacerbated toxicity 
seen when the Grx1 homolog is genetically ablated in models of familial and sporadic PD.
[ 20]. Hence, further studies are warranted to examine the synergistic impact of 
dysregulation of glutathionylation on neuronal cell survival mechanisms involving DJ-1 and 
Akt.
Therapeutic advancement in the general PD population has not changed greatly since the 
introduction of levodopa as the primary therapy for PD in the 1960’s. Currently there are no 
therapeutic approaches available to slow the progression of dopaminergic degeneration. The 
ideal intervention would slow or even reverse the degeneration of dopaminergic neurons by 
targeting a dysregulated pathway common to both familial and sporadic PD. Although 
familial mutations represent only approximately 10 percent of all PD cases, post-
translational modifications mimicking the functional consequences of the genetic mutations 
may play a role in the development of sporadic PD. In our previous study post-mortem PD 
brain tissue was found to have diminished levels of Grx1 [20], supporting the possibility that 
glutathionylation of key proteins involved in PD development/progression may contribute to 
PD pathogenicity. Our current data are consistent with the idea that glutathionylation of DJ-1 
results in its degradation leading to decreased protein levels. This loss of DJ-1 protein 
mimics the outcome of the pathogenic L166P mutation that results in reduced steady-state 
levels of DJ-1 [ 48]. A search of the database dbGSH reveals that several other proteins 
implicated in the etiology of PD are susceptible to glutathionylation [43]. These proteins 
include VPS35, UCH-L1, and EIF4G1. Although these proteins can be glutathionylated, it is 
unclear if glutathionylation affects the function of these proteins in an analogous manner to 
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pathogenic mutations, so further study is warranted. Nevertheless, the potential impact of 
deficient Grx1 on glutathionylation status and function of proteins implicated in PD suggests 
that pharmacologically increasing Grx1 activity in neurons may decrease dopaminergic 
toxicity by regulating not only DJ-1 protein content, but also other downstream targets that 
are altered via glutathionylation.
Statistical analysis
Statistical analyses of the reported data, as noted in the figure legends, were performed using 
ANOVA followed by Tukey’s post hoc test, Student’s t-Test, or one-way linear regression. 
All statistical analyses were run using Microsoft Excel or GraphPad Prism.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
ATCC American Type Culture Collection
C. elegans Caenorhabditis elegans
Grx1 Glutaredoxin 1
GSH Glutathione
GSSG Glutathione disulfide
Protein-SSG Glutathionylated protein
HPLC High performance liquid chromatography
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PBMCs Human peripheral blood mononuclear cells
DJ-1-SSG Glutathionylated DJ-1
LRRK2 Leucine Rich Repeat Kinase 2
LC-MS Liquid chromatography-mass spectrometry
m/z Mass/charge ratio
MS Mass spectrometry (mass spectrometric)
NGM Nematode growth media
PD Parkinson’s disease
TBST Tris-buffered saline with 0.05% Tween-20
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Figure 1. DJ-1 protein content is regulated by Grx1 in vivo
(A) Western blot analyses of midbrain homogenates from WT and Grx1−/− mice probed with 
anti-Grx1, anti-DJ-1, and anti-actin antibodies, respectively. (B) Quantification of DJ-1 
protein content (normalized to actin) in the lysates of midbrain samples from WT and 
Grx1−/− mice; n = 6 independent WT and Grx1−/− mice/*p<0.05. Statistical analysis was 
completed using Student’s T-test. Error bars represent SEM. (C) Positive correlation 
between the protein contents of DJ-1 and Grx1 (normalized to actin) in human PBMCs; n = 
14 independent biological samples/p<0.01, R2=0.54. Statistical analysis was completed 
using a one-way linear regression test. (D) Positive correlation between the contents of the 
DJ-1 and Grx1 proteins (normalized to actin) in lysates of human post mortem midbrain 
tissue; n = 14 independent biological samples/p<0.01, R2=0.63. Statistical analysis was 
completed using a one-way linear regression test.
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Figure 2. DJ-1 protein content is diminished after treatment with glutathionylation-inducing 
agents
(A) Representative western blot analysis of lysates from SH-SY5Y cells treated with 
increasing concentrations of H2O2. The blot was partitioned and probed with anti-DJ-1 or 
anti-actin, respectively. (B) Quantification of normalized DJ-1 content after H2O2 treatment; 
n = 8 independent biological replicates. (C) Representative western blot analysis of lysates 
from SH-SY5Y cells pretreated with DMSO, or a broad protease inhibitor cocktail (PI, see 
Methods); then treated with PBS or 0.1 mM diamide. The blot was partitioned and probed 
with anti-DJ-1 or anti-actin, respectively. Lane 1, DMSO + PBS; lane 2, DMSO + diamide; 
lane 3, PI + PBS; lane 4, PI + diamide. (D) Quantification of normalized DJ-1 content after 
diamide and PI treatments; n=8 independent biological replicates. (E) Representative 
western blot analysis of lysates from SH-SY5Y cells pretreated with DMSO, MG-132, or 
lactacystin; then treated with PBS or 0.1 mM diamide. The blot was partitioned and probed 
with anti-β-catenin, anti-DJ-1, and anti-actin, respectively. (F) Quantification of DJ-1 
protein content (normalized to actin); n = 8 independent biological replicates. Statistical 
analyses for quantifications shown in (B), (D), and (F) were completed using ANOVA 
followed by Tukey’s post hoc test. Error bars on quantification for (B), (D), and (F) 
represent SEM.
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Figure 3. DJ-1 is glutathionylated in vivo and in vitro
(A) Representative western blot analysis of immunopreciptated DJ-1 from mouse brain 
homogenate probed with anti-glutathione (GSH) antibody. Replicate analyses of four 
independent biological samples gave similar results. Arrow denotes a band of 
immunoreactivity at approximately 45 kDa. (B) Immunopreciptated DJ-1 recognized by 
anti-DJ-1 antibody. The blot shown in (A) was stripped and re-probed with anti-DJ-1 
antibody. Again, this was replicated with the four different samples. Arrow denotes a band 
of immunoreactivity at approximately 45 kDa. Overlay of the films shown in panels A and B 
documented coincidence of the 45 kDa band, representing glutathionylated DJ-1. (C) 
Electrospray ionization mass spectrum of intact recombinant DJ-1. The mass spectrum 
shows a distribution of charged states (+11 to +28) for intact DJ-1 protein. Deconvolution of 
the spectrum reveals a protein mass of 20036.3 Da, which is identical to the theoretical mass 
of recombinant DJ-1. (D) Electrospray ionization mass spectrum of glutathionylated DJ-1. 
Incubation of DJ-1 protein with 5 mM GSH and 1 mM diamide led to an increase in protein 
mass of 305-Da (blue ion series, deconvoluted mass = 20341.5 Da) or 610-Da (red ions 
series, deconvoluted mass = 20646.7 Da), corresponding to covalent modification of DJ-1 
with one or two glutathione moieties, respectively.
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Figure 4. 
Identification of the glutathionylation sites of DJ-1 by tandem mass spectrometry. Selective 
Ion chromatographs of tryptic digest of DJ-1 treated with 5 mM GSH and 1 mM diamide 
revealed two Cys containing peptides (C) DVVIC53PDASLEDAK (m/z = 766.5 [M+2H]+2) 
and (D) GLIAAIC106AGPTALLAHEIGFGSK (m/z = 1258.2 [M+2H]+2), with 
corresponding masses increased by 305-Da as compared to the untreated sample shown in 
(A) and (B). (E) and (F): MS/MS fragmentation pattern of these peptides identifies Cys53 
and Cys106 residues as the sites of glutathionylation. According to Biemann nomenclature, 
the series of b and y ions are identified in the mass fragmentograms and in the diagrams of 
the Cys-containing peptides at the top of panels E and F. For example, the site of 
glutathionylation at Cys-53 is identified by the loss of 408 mass units for the y9 ion versus 
the y10 ion, corresponding to the loss of the cysteinylglutathione moiety.
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Figure 5. Loss of DJR-1.2 induces PD phenotypes in C. elegans, exacerbates mutant LRRK2-
mediated impairment of dopamine dependent behavior, but does not consistently exacerbate 
mutant LRRK2-mediated dopaminergic neurodegeneration
(A) Representative PCR analysis of LRRK2 (upper panel) and WT djr-1.2 or mutant djr-1.2 
DNA (lower panel) in C. elegans lines. Primers of djr-1.2 were designed to generate two 
distinct PCR products depending on the inclusion (upper band) or exclusion (lower band) of 
the first exon of djr-1.2 in the C. elegans lines. (B) Basal slowing data demonstrating that 
loss of DJR-1.2 results in dysfunction of dopamine-dependent movement, and exacerbates 
R1441C- and G2019S-mediated dysfunction of dopamine-dependent movement; *p<0.05, 
comparing control to djr-1.2−/−; #p<0.05, comparing R1441C to R1441C; 
djr-1.2−/−; &p<0.05, comparing G2019S to G2019S; djr-1.2−/−. (C) Dopaminergic 
degeneration data demonstrating that loss of DJR-1.2 results in late onset degeneration, but 
does not exacerbate mutant LRRK2-mediated degeneration consistently. ^p<0.05 comparing 
control to djr-1.2−/−, $p<0.05 comparing R1441C to R1441C; djr-1.2−/−. For (B) and (C) 
error bars represent SEM. n = 3 independent groups of worms for all days, ~10 worms (B) 
or ~30 worms (C) per genotype per experiment. Statistical analysis was completed using 
one-way ANOVA followed by Tukey’s post-hoc test. Statistical comparisons between WT 
and LRRK2 expressing lines recapitulated previously published experimental data [20], and 
were not included to simplify the figure.
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Figure 6. Over-expression of DJR-1.2 partially compensates for the loss of GLRX-10
(A) PCR analysis of LRRK2 (upper panel), WT or mutant glrx-10 DNA (middle panel), and 
coding DNA sequence (CDS) of djr-1.2 (lower panel) indicating the generation of R1441C; 
glrx-10−/−; vector (mCherry) and R1441C; glrx-10−/−; DJR-1.2-mCherry expressing C. 
elegans lines. (B) Fluorescent images of the head region of the newly generated C. elegans 
depicting the expression of Pdat-1::mCherry and Pdat-1::DJR-1.2:mCherry in the 
dopaminergic neurons. Expression of GFP tagged dopaminergic neurons co-localize with 
expression of both Pdat-1::mCherry and Pdat-1::DJR-1.2::mCherry indicating dopaminergic 
expression of mCherry and DJR-1.2-mCherry, respectively. (C) Basal slowing data 
demonstrating that over-expression of DJR-1.2 partially recues the LRRK2-R1441C 
mediated dysfunction of dopamine-dependent movement in the glrx-10−/− background. 
*p<0.05 compared to R1441C; glrx-10−/−; vector. Error bars represent SEM. n = 3 
independent groups of worms for all days, 10 worms per genotype per experiment. 
Statistical analysis was completed using one way ANOVA followed by Tukey’s post-hoc 
test.
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Supplemental Figure Legends 
S1. QPCR and Western blot data for transgenic Grx1 and WT mice. (A) QPCR analysis of DJ-1 mRNA from 
WT and Grx1-/- mice in the C57BL/6 background. N=3 mice per group, no statistical difference via Student’s T-
Test. (B) Western blot analysis of transgenic mice over-expressing hGrx1; tissue probed with anti-Grx1, anti-
DJ-1, and anti-actin antibodies, respectively. (C) Western blot analysis of WT and Grx1-/- mice in the BALB/c 
background; tissue probed with anti-Grx1, anti-DJ-1, and anti-actin antibodies, respectively. N=3 mice per 
group. (D) QPCR analysis of DJ-1 mRNA from WT and Grx1-/- mice in the BALB/c background. N=3 mice per 
group, no statistical difference via Student’s T-Test. 
 
S2. Western blot data for human samples. (A) Western blot analysis of samples extracted from human PBMCs 
probed with anti-Grx1, anti-DJ-1, and anti-actin antibodies, respectively; n= 14 independent biological samples. 
(B) Western blot analysis of samples extracted from human midbrain tissue probed with anti-Grx1, anti-DJ-1, 
and anti-actin antibodies, respectively; n = 14 independent biological samples. 
 
S3. Validation of the DJ-1 antibody. (A) Western blot analysis of immunopreciptated DJ-1. Left lane, reduced 
(+ DTT); right lane, non-reduced ( - DTT). (B) Western blot analysis of brain tissue homogenates from DJ-1-/- 
and WT mice treated with DTT and probed with anti-DJ-1, and anti-actin antibodies, respectively. N=2 mice 
per genotype.   
 
S4. Validation of the DJ-1 glutathionylation. DJ-1 was immunoprecipitated from mouse brain lysate, run under 
non-reducing conditions and transferred to PVDF membrane. Half of the blot was soaked in TBST buffer with-
out DTT, and the other half was soaked in TBST buffer containing 100 mM DTT. The blots then were probed 
with the anti-GSH antibody, stripped, and re-probed with the anti-DJ-1 antibody for confirmation of DJ-1 pro-
tein. Loss of anti-GSH signal in the presence of DTT indicates that the disulfide reducing agent ablates the anti-
GSH signal consistent with loss of the glutathionyl mixed disulfide adduct of DJ-1 (A) Western blot analysis of 
the membrane incubated with TBST (B) Western blot analysis of membrane incubated in TBST and DTT. Ar-
rows indicate the ~45 kDa immunoreactive band. 
 
S5. Quantification of glutathionylated DJ-1 peptides. (A) and (B) represent selective ion chromatograms for two 
cysteine-containing DJ-1 peptides unmodified by glutathionylation; (C) and (D) correspond to the same pep-
tides obtained from 15N-labeled DJ-1, serving as internal standards. Areas under the ion intensity peaks, colored 
in gray were used to calculate ratios between 15N-enriched and natural abundance peptides to determine the 
fraction of each peptide covalently modified by glutathione. (E) and (F) represent MS spectra averaged at the 
peak of ion intensities for DVVIC53PDASLEDAK and GLIAAIC106AGPTALLAHEIGFGSK peptides, 
respectively. Ions and their isotopic distribution for both 15N-enriched (blue) and natural abundance (black) 
peptides are shown. 
 
S6. Quantification of mCherry and DJR-1.2:mCherry protein content in the dopaminergic neurons of C. elegans 
by fluorescence microscopy. Quantification indicates that content of mCherry and DJ-1:mCherry protein (rela-
tive to GFP expression specifically in the dopaminergic neurons) are equivalent and do not change over time. 
 
S7. Quantification of relative DJ-1 protein content in Neuro-2A cells transfected with scRNA/Grx1 shRNA and 
treated with individual protease inhibitors from the protease inhibitor cocktail. Neuro-2A cells transfected with 
scRNA/Grx1 shRNA were treated with individual protease inhibitors or with DMSO (D; vehicle) for 48 hr with 
fresh medium containing inhibitor or vehicle replaced every 12 hr. Panels show representative Western blots of 
DJ-1 along with respective loading control β-tubulin (Tub) and densitometric analyses. The inhibitors added 
with scRNA/shRNA are: (A) 52 µM 4-(2-aminoethyl) benzenesulfonyl fluoride, (Ae), (B) 40 nM aprotinin, 
(Ap), (C) 2 µM bestatin (Be), (D) 700 nM E-64 (E64), (E) 1 µM leupeptin (Le) and (F) 750 nM pepstatin A 
(Pe). All data were analyzed using one-way ANOVA followed by Student-Newman-Keuls test to determine 
significant differences with * representing p < 0.05. n = 3-6 independent samples in each experimental group. 
None of the individual protease inhibitors tested alone afforded protection of DJ-1 from degradation, unlike the 
complete cocktail. 
DJ-­‐1	  
Grx1	  
Ac+n	  
	  	  	  WT	   GRX1-­‐/-­‐	  
BALB/c	  
C)	  
DJ-­‐1	  
Grx1	  
Ac+n	  
25	  kDa	  
20	  kDa	  	  
15	  kDa	  
10	  kDa	  
75	  kDa	  
50	  kDa	  
37	  kDa	  
Grx1	  TG	  WT	  B)	  
Supplemental	  Figure	  S1	  	  
0	  
0.2	  
0.4	  
0.6	  
0.8	  
1	  
1.2	  
1.4	  
WT	   Grx1	  K/O	  
DJ
-­‐1
	  m
RN
A	  
(R
el
a+
ve
	  to
	  G
AP
DH
)	  
0	  
0.2	  
0.4	  
0.6	  
0.8	  
1	  
WT	   Grx1	  K/O	  
DJ
-­‐1
	  m
RN
A	  
(R
el
a+
ve
	  to
	  G
AP
DH
)	  
A)	  
D)	  
BALB/c	  25	  kDa	  
20	  kDa	  	  
15	  kDa	  
10	  kDa	  
50	  kDa	  
37	  kDa	  
Ac+n	  
DJ-­‐1	  
Grx1	  
A)	  
Supplemental	  Figure	  S2	  	  
20	  kDA	  
25	  kDA	  
37	  kDA	  
50	  kDA	  
10	  kDA	  
15	  kDA	  
1	  	  	  	  2	  	  	  	  	  3	  	  	  	  	  	  4	  	  	  	  	  	  5	  	  	  	  	  	  6	  	  	  	  	  7	  	  	  	  	  	  8	  	  	  	  	  	  	  	  	  	  9	  	  	  	  10	  	  	  11	  	  	  12	  	  	  	  13	  	  	  	  14	  	  	  	  	  
DJ-­‐1	  
Ac+n	  
Grx1	  
37	  kDA	  
50	  kDA	  
10	  kDA	  
15	  kDA	  
20	  kDA	  
25	  kDA	  
B)	  
10	  kDa	  
15	  kDa	  
20	  kDa	  
25	  kDa	  
37	  kDa	  
50	  kDa	  
75	  kDa	  
100	  kDa	  
25	  kDa	  
37	  kDa	  
50	  kDa	  
75	  kDa	  
WT	  
#1	  
WT	  
#2	  
DJ-­‐1	  
K/O	  
#1	  
DJ-­‐1	  
K/O	  
#2	  
WB:	  DJ-­‐1	  
WB:	  Ac+n	  
10	  kDa	  
15	  kDa	  
25	  kDa	  
37	  kDa	  
50	  kDa	  
75	  kDa	  
100	  kDa	  
150	  kDa	  
20	  kDa	  
-­‐DTT	  +DTT	  
IP:	  
DJ-­‐1	  
	  
WB:	  
DJ-­‐1	  
A)	   B)	  
Supplemental	  Figure	  S3	  	  
An+-­‐GSH	  
An+-­‐DJ-­‐1	  
-­‐DTT	  
Incuba+on	  
+DTT	  
Incuba+on	  
Supplemental	  Figure	  S4	  	  
37	  kDa	  
50	  kDa	  
75	  kDa	  
100	  kDa	  
A B
IP	  	  	  	  	  	  IgG	   IP	  	  	  	  	  	  IgG	  
37	  kDa	  
50	  kDa	  
75	  kDa	  
100	  kDa	  
Supplemental	  Figure	  S5	  	  
15 20 25
Time  (min)
0
25
50
75
100
15 20 25
Time  (min)
8 10 12 14 16 18
Time  (min)
Time  (min)
DVVI CPDASLEDAK  
m/z  =  766.5  [M+2H]
DVVI CPDASLEDAK  (      N)  
m/z  =  773.8  [M+2H]
GLIAAI CAGPTALLAHEIGFGSK  
m/z  =  756.4  [M+3H]
GLIAAI CAGPTALLAHEIGFGSK  (      N)  
m/z  =  765.1  [M+3H]
2+
2+ 3+
3+
R
ea
tiv
e  
ab
un
da
nc
e
0
25
50
75
100
0
25
50
75
100
0
25
50
75
100
R
ea
tiv
e  
ab
un
da
nc
e
R
ea
tiv
e  
ab
un
da
nc
e
R
ea
tiv
e  
ab
un
da
nc
e
8 10 12 14 16 18
0
25
50
75
100
0
25
50
75
100
15 15
R
ea
tiv
e  
ab
un
da
nc
e
R
ea
tiv
e  
ab
un
da
nc
e
766.4
766.9
767.4
773.9
774.4
774.9
775.4
765.1
765.4
765.7
766.0756.7
756.4
757.0
757.3
760 765 770 775 780 750 755 760 765 770
A B
C D
EF
53 106
53 106
A	   	  
C	   D	  
E	   F	  
Supplemental	  Figure	  S6	  	  
0	  
0.1	  
0.2	  
0.3	  
0.4	  
0.5	  
0.6	  
0.7	  
0.8	  
0.9	  
1	  
mCherry-­‐Day	  0	   mCherry-­‐Day	  2	   DJ:mCherry-­‐Day	  0	   DJ:mCherry-­‐Day	  2	  
RF
P/
GF
P	  
Ra
(o
	  
Supplemental	  Figure	  S7	  	  
Supplemental	  Tables	  	  
Pa+ent	  Refernce	  #	   Age	   Sex	   Diagnosis	  
137	   62	   F	   PD	  
219	   67	   M	   PD	  
228	   77	   M	   PD	  
236	   67	   M	   PD	  
254	   65	   M	   PD	  
256	   74	   M	   PD	  
257	   80	   M	   PD	  
260	   46	   M	   PD	  
262	   73	   M	   PD	  
264	   57	   M	   PD	  
266	   70	   M	   PD	  
268	   64	   M	   PD	  
270	   75	   M	   PD	  
271	   58	   F	   PD	  
Patient information for PBMC analysis Patient information for brain lysate analysis A B	  
C	  
Designation Genotype Strain Reference 
Control (GFP) lin-15(n765ts)X; cwrIs730[Pdat-1::GFP, lin-15(+)] SGC730 [6] 
R1441C lin-15(n765ts)X; cwrIs851[Pdat-1::GFP, Pdat-1::LRRK2(R1441C), lin-15(+)] SGC851 [6] 
G2019S lin-15(n765ts)X; cwrIs856[Pdat-1::GFP, Pdat-1::LRRK2(G2019S), lin-15(+)] SGC856 [6] 
R1441C; glrx-10−/− glrx-10(tm4634)I; cwrIs851 SGC302 [20] 
djr-1.2-/-  djr-1.2(tm1348)V  tm1346  NBP 
R1441C; djr-1.2-/-                                      djr-1.2(tm1348)V; cwrIs851      SGC10 This study 
G2019S; djr-1.2-/-                             djr-1.2(tm1348)V; cwrIs856           SGC11 This study 
R1441C; glrx-10-/-; DJR-1.2   glrx-10(tm4634)I; cwrIs851; cwrEx20[Pdat-1::DJR-1.2::mCherry] SGC20 This study 
R1441C; glrx-10-/-; Vector   glrx-10(tm4634)I; cwrIs851; cwrEx22[Pdat-1::mCherry] SGC22 This Study 
NBP: National Bioresource Project (Japan)  
Cases	  used	  for	  Western	  blot	  analysis	  from	  PBMC	  lysate.	  	   Cases	  used	  for	  Western	  blot	  analysis	  from	  post	  mortem	  midbrain	  +ssue.	  	  
Caenorhabdi+s	  elegans	  strains	  used	  in	  this	  study	  	  
Pa+ent	  
Refernce	  #	   Sex	   Age	   Diagnosis	  
P08-­‐40	   F	   86	   PD	  
P08-­‐41	   F	   83	   PD	  
P08-­‐42	   M	   75	   PD	  
P08-­‐43	   M	   71	   PD	  
P08-­‐34	   M	   51	   Control	  
P08-­‐35	   M	   89	   Control	  
P08-­‐36	   F	   86	   Control	  
P08-­‐37	   M	   73	   Control	  
P08-­‐38	   M	   69	   Control	  
PD1	   M	   77	   PD	  
PD2	   F	   49	   PD	  
PD3	   F	   61	   PD	  
PD4	   M	   73	   PD	  
